Reações infusionais imediatas a agentes imunobiológicos endovenosos no tratamento de doenças autoimunes: experiência de 2.126 procedimentos em um centro de infusão não oncológico

Introducao: Com o crescimento do uso de drogas imunobiologicas (IBD) ampliamos o conhecimento sobre sua eficacia e seguranca.Objetivo: Analisar as reacoes infusionais imediatas (RII) as IBD endovenosas - infliximabe (IFX), rituximabe (RTX), abatacepte (ABT) e tocilizumabe (TCZ) - no tratamento de doencas autoimunes.Metodo:Avaliamos 2.126 infusoes feitas no CID (Centro de Infusao) em 268 pacientes. A droga usada, a indicacao clinica, o tempo de infusao e o uso de pre-medicacao foram determinados pelo medico prescritor. Foram consideradas RII todas as intercorrencias apresentadas durante a infusao e/ou periodo observacional de 30 minutos. A conduta adotada nas RII seguiu os protocolos do CID.Resultados: Em relacao ao tipo de IBD, as infusoes foram distribuidas em: IFX (1.584; 74,5%), TCZ (226; 10,63%), RTX (185; 8,7%) e ABT (131; 6,16%). As RII foram descritas em 87 procedimentos (4,09%): 77 no grupo IFX e 10 no grupo RTX. Nao foram descritas RII nos grupos de ABT e TCZ. A maioria foi considerada leve (n = 5; 41,17%) ou moderada (n = 50; 58,81%) e nao houve reacoes graves. Das infusoes interrompidas, 79 (92,9%) foram reiniciadas e concluidas com exito. Apenas seis (0,28%) nao foram concluidas por causa das RII.Conclusao:Apesar da diferenca entre o numero de procedimentos por droga, trata-se de uma analise de "vida real", na qual a incidencia de RII foi semelhante a descrita na literatura. A baixa incidencia de RII corrobora os dados de seguranca tanto de forma quantitativa como qualitativa e ressalta a importância do acompanhamento medico especializado durante a infusao.

• Publication year

  2014

• Venue

  Revista Brasileira De Reumatologia

• Publication date

  2014-03-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/J.RBR.2014.03.004
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies

  2012cited by this paper
• Drug Class Review: Targeted Immune Modulators: Final Update 3 Report

  2012cited by this paper
• [Incidence and management of infusion reactions to infliximab in 186 italian patients with rheumatoid arthritis: the Padua experience].

  2011cited by this paper
• Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

  2011cited by this paper
• How to manage hypersensitivity reactions to biological agents?

  2011cited by this paper
• Infusion reactions: diagnosis, assessment, and management.

  2010cited by this paper
• Immediate complications of 3,555 injections of anti-TNFα.

  2010cited by this paper
• Tocilizumab for the treatment of rheumatoid arthritis

  2010cited by this paper
• Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.

  2009cited by this paper
• Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

  2008cited by this paper
• Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.

  2008cited by this paper
• The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

  2008cited by this paper
• Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis

  2007cited by this paper
• Cytokine-release syndrome: overview and nursing implications.

  2007cited by this paper
• Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management.

  2007cited by this paper
• Management and preparedness for infusion and hypersensitivity reactions.

  2007cited by this paper
• Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

  2007cited by this paper
• - 1-Predictors of infusion reactions during infliximab treatment in patients with arthritis

  2006cited by this paper
• Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

  2006cited by this paper
• Tolerability and safety of rituximab (MabThera).

  2005cited by this paper
• Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.

  2005cited by this paper
• Infusion Reactions Associated with the Therapeutic Use of Monoclonal Antibodies in the Treatment of Malignancy

  2004cited by this paper
• Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number.

  2004cited by this paper
• Unique aspects of supportive care using monoclonal antibodies in cancer treatment.

  2003cited by this paper
• Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?

  2003cited by this paper
• Original contributionThe incidence and management of infusion reactions to infliximab: a large center experience

  2003cited by this paper
• Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

  2003cited by this paper
• Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.

  2002cited by this paper
• Prevention and Management of Antineoplastic-Induced Hypersensitivity Reactions

  2001cited by this paper
• Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.

  2000cited by this paper
• Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.

  1999cited by this paper
• IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

  1997cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Drug-induced nephrotoxicity and its reversal using botanicals of traditional Indian medicine in different animal models: way forward

  2025cites this paper
• Atuação do reumatologista nos Centros de Dispensação de Medicação de Alto Custo (CEDMAC)

  2023cites this paper
• Caracterização dos pacientes atendidos no centro de infusão do ambulatório de uma Universidade do Estado do Rio de Janeiro, Brasil

  2021cites this paper
• Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches

  2020cites this paper
• Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year

  2018cites this paper
• REAÇÕES ADVERSAS IMEDIATAS AOS MEDICAMENTOS IMUNOBIOLÓGICOS ADMINISTRADOS PARA TRATAMENTO DE DOENÇAS REUMÁTICAS PEDIÁTRICAS EM CENTRO DE INFUSÃO

  2017cites this paper
• AVALIAÇÃO CLÍNICA, SOCIODEMOGRÁFICA E DE REAÇÕES INFUSIONAIS DE PACIENTES REUMATOLÓGICOS ATENDIDOS EM UMA CLÍNICA DE TERAPIA IMUNOBIOLÓGICA ASSISTIDA

  2017cites this paper
• Biologic therapy-induced pemphigus*

  2017cites this paper
• To pretreat or not to pretreat? The experience of three Italian Psoriasis centres on the use of premedication with Infliximab

  2016cites this paper
• Infliximab-Related Infusion Reactions: Systematic Review

  2015cites this paper